

EISAI' S INVESTIGATIONAL ANTICANCER AGENT ERIBULIN MESYLATE (E7389)

RER 001103710 (015) 10 To 009 T (0010) 2 Eribulin 0206 T (0105) 03 (0104)
Eisai
Eisai
Eisai

Eisai defines oncology as a therapeutic area of focus and is committed to the development of novel anticancer agents and treatments for supportive care. Through these efforts, Eisai will make further contributions to addressing the diversified needs of patients and their families as well as healthcare professionals.

Media Inquiries:
Public Relations Department,
Eisai Co., Ltd.
+81-(0)3-3817-5120

luc